Amylin Signaling: The Second Satiety Hormone Reshaping Obesity Drugs

If GLP-1 has dominated the obesity conversation, amylin is the hormone increasingly sharing the spotlight. Co-secreted with insulin and acting through its own receptor system, amylin curbs appetite by a route that partly overlaps with, but is distinct from, GLP-1. That distinctness is exactly why drug developers are racing to harness it — as stand-alone amylin analogs and, more prominently, as partners for GLP-1 in combination therapies.

What amylin is

Amylin, also called islet amyloid polypeptide (IAPP), is a 37-amino-acid peptide hormone produced by the same pancreatic beta cells that make insulin, and released alongside insulin in response to meals. So insulin and amylin travel together as a coordinated post-meal signal: insulin manages glucose disposal, while amylin helps control how much and how fast food enters the system and how full you feel.

Its major physiological actions are complementary to insulin's. Amylin slows gastric emptying, suppresses the post-meal rise in glucagon (which would otherwise push glucose up), and promotes satiety — the sensation of fullness that ends a meal. Together these blunt post-meal glucose spikes and reduce food intake.

How amylin receptor signaling works

Amylin's satiety effect is centered in the brainstem, particularly the area postrema — a region that lacks a full blood-brain barrier and can sense circulating signals directly. From there, amylin engages circuits that reduce appetite and reinforce meal termination.

The amylin receptor itself is not a single dedicated protein but a complex: the calcitonin receptor combined with receptor-activity-modifying proteins (RAMPs). Different RAMP pairings create the receptor subtypes that give amylin its specific pharmacology, and this shared machinery with the calcitonin receptor is why some amylin analogs also have calcitonin-receptor activity. Understanding this receptor complex has been central to designing long-acting amylin drugs.

Why amylin complements GLP-1

Amylin and GLP-1 both reduce appetite and slow gastric emptying, so at first glance they look redundant. But they act through different receptors and partly different brain circuits, and in practice their effects add up rather than simply overlapping. Combining them tends to produce greater weight loss than either alone — the core rationale behind the newest obesity drugs.

There is also interest in amylin's potential effect on the quality of weight loss and on the body's defense of an elevated fat mass. Amylin signaling may help counter some of the compensatory drive that makes weight regain so common, and amylin-based approaches are often discussed as potentially preserving a more favorable balance of fat versus lean tissue, though these ideas are still being established in trials.

From native amylin to drugs

Native amylin is impractical as a medicine — it is sticky and prone to aggregation (the "amyloid" in its name reflects deposits found in the pancreas in type 2 diabetes). The solution was engineering.

• Pramlintide was the first amylin analog brought to the clinic, a modified, non-aggregating version used as a mealtime injection alongside insulin in diabetes. It validated amylin as a druggable target but required frequent dosing.
• Cagrilintide is a long-acting amylin analog designed for once-weekly dosing, studied both alone and, most notably, as the amylin half of CagriSema in combination with semaglutide.
• Petrelintide is another long-acting amylin analog in development, pursued as monotherapy and as a combination backbone.
• Amycretin folds amylin and GLP-1 agonism into a single molecule rather than combining two drugs.

This progression — from a mealtime adjunct to weekly analogs to unimolecular co-agonists — mirrors the same engineering arc that transformed GLP-1 therapy.

Amylin in metabolic disease

Beyond appetite, amylin biology intersects with diabetes in a second way: the aggregation of IAPP into amyloid deposits in pancreatic islets is a feature of type 2 diabetes and may contribute to beta-cell stress. This is a different aspect of amylin from its satiety signaling, and it is one reason amylin has long been of scientific interest in diabetes research, though the therapeutic focus today is squarely on harnessing amylin's appetite-regulating actions for weight management.

Key takeaways

• Amylin is a satiety hormone co-secreted with insulin from pancreatic beta cells; it slows gastric emptying, suppresses glucagon, and promotes fullness.
• It acts largely through the brainstem area postrema, via a receptor complex built from the calcitonin receptor plus RAMP proteins.
• Amylin's mechanism is complementary to GLP-1, so combining the two produces greater weight loss than either alone — the rationale behind drugs like CagriSema and amycretin.
• Engineering non-aggregating, long-acting analogs (pramlintide, cagrilintide, petrelintide) turned amylin from a difficult native peptide into one of the most important targets in modern obesity medicine.
• These agents are variously approved or investigational; this overview is educational and not a recommendation to source research peptides.